Literature DB >> 8628612

Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project.

H X Barnhart1, M B Caldwell, P Thomas, L Mascola, I Ortiz, H W Hsu, J Schulte, R Parrott, Y Maldonado, R Byers.   

Abstract

OBJECTIVE: To describe the progression of human immunodeficiency virus (HIV) disease through clinical stages from birth to death among a large number of perinatally infected children.
METHODS: The Pediatric Spectrum of Disease (PSD) project, coordinated by the Centers for Disease Control and Prevention (CDC), has conducted active surveillance for HIV disease since 1988 in seven geographic regions. PSD data are collected from medical and social service records every 6 months through practitioners at each participating hospital clinic. We analyzed data from perinatally HIV-infected children born between 1982 and 1993. The natural history of HIV disease was divided into five progressive stages using the clinical categories in the CDC 1994 pediatric HIV classification system: stage N, no signs or symptoms; stage A, mild signs or symptoms; stage B, moderate signs or symptoms; stage C, severe signs or symptoms; and stage D, death. A five-stage Markov model was fitted to the PSD data. To compare the estimates from the PSD project with the published estimates, we also fitted an alternative Markov model using acquired immunodeficiency syndrome (AIDS; 1987 case definition) in place of stage C and also calculated standard Kaplan-Meier estimates.
RESULTS: A total of 2148 perinatally HIV-infected children were included in the analysis. The estimated mean times spent in each stage were: N, 10 months; A, 4 months; B, 65 months; and C, 34 months. We estimated that a child born with HIV infection has a 50% (95% confidence interval [CI], 40%-60%) chance of severe signs or symptoms developing by 5 years of age and a 75% (95% CI, 68%-82%) chance of surviving to 5 years of age. For a child in stage B, there is a 60% (95% CI, 49%-71%) chance of severe signs or symptoms developing within the next 5 years and a 65% (95% CI, 56%-73%) chance of surviving 5 more years. The estimated mean time from birth to stage C was 6.6 (95% CI, 5.7-7.5) years, and the estimated mean survival time from birth was 9.4 (95% CI, 8.1-10.7) years. From the alternative Markov model, the estimated mean time from birth to AIDS was 4.8 (95% CI, 4.5-5.2) years.
CONCLUSION: Markov modeling using the revised pediatric classification system allowed us to describe the natural history of HIV disease in children before diagnosis of AIDS. On average, children progress to moderate symptoms in the second year of life and then remain moderately symptomatic for more than half of their expected lives, underscoring their need for clinical care before the onset of AIDS. The results from the Markov model are useful in family counseling, health care planning, and clinical trial designs.

Entities:  

Mesh:

Year:  1996        PMID: 8628612

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Universal HIV testing in pregnancy.

Authors:  S Ratnapalan; O Diav-Citrin; S M King; G Koren
Journal:  Can Fam Physician       Date:  2000-03       Impact factor: 3.275

Review 2.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

Review 3.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

4.  Cognition, Emotional Health, and Immunological Markers in Children With Long-Term Nonprogressive HIV.

Authors:  Robert Paul; Tanakorn Apornpong; Wasana Prasitsuebsai; Thanyawee Puthanakit; Vonthanak Saphonn; Linda Aurpibul; Pope Kosalaraksa; Suparat Kanjanavanit; Wicharn Luesomboon; Chaiwat Ngampiyaskul; Tulathip Suwanlerk; Kea Chettra; William T Shearer; Victor Valcour; Jintanat Ananworanich; Stephen Kerr
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-01       Impact factor: 3.731

5.  Human immunodeficiency virus-related mortality in infants and children: data from the pediatric pulmonary and cardiovascular complications of vertically transmitted HIV (P(2)C(2)) Study.

Authors:  C Langston; E R Cooper; J Goldfarb; K A Easley; S Husak; S Sunkle; T J Starc; A A Colin
Journal:  Pediatrics       Date:  2001-02       Impact factor: 7.124

6.  Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.

Authors:  Maximillian Rosario; John Fulkerson; Shamit Soneji; Joe Parker; Eung-Jun Im; Nicola Borthwick; Anne Bridgeman; Charles Bourne; Joan Joseph; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

Review 7.  Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.

Authors:  Stephanie Shiau; Louise Kuhn
Journal:  Expert Rev Anti Infect Ther       Date:  2014-02-09       Impact factor: 5.091

8.  Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group.

Authors:  S E Lipshultz; K A Easley; E J Orav; S Kaplan; T J Starc; J T Bricker; W W Lai; D S Moodie; K McIntosh; M D Schluchter; S D Colan
Journal:  Circulation       Date:  1998-04-07       Impact factor: 29.690

9.  Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

10.  Routine prenatal screening for HIV in a low-prevalence setting.

Authors:  D M Patrick; D M Money; J Forbes; S R Dobson; M L Rekart; D A Cook; P J Middleton; D R Burdge
Journal:  CMAJ       Date:  1998-10-20       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.